Wnt/β-catenin signaling regulates MAPK and Akt1 expression and growth of hepatocellular carcinoma cells

Neoplasma

Volumn 58, Issue 3, 2011, Pages 239-244

  Wang, X H ^a,b   Meng, X W ^a   Sun, X ^a   Liu, B R ^b   Han, M Z ^b   Du, Y J ^b   Song, Y Y ^b   Xu, W ^b  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

AKT1; Hepatocellular carcinoma; MAPK; Signaling pathway; catenin

Indexed keywords

AKT 1 PROTEIN; BETA CATENIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; WNT PROTEIN; AKT1 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; PROTEIN KINASE B;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; INHIBITION KINETICS; LIVER CELL CARCINOMA; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL STRAIN HEPG2; GENETICS; HUMAN; LIVER TUMOR; PATHOLOGY; PHYSIOLOGY;

BETA CATENIN; CARCINOMA, HEPATOCELLULAR; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 79958159965     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_03_239     Document Type: Article

References (29)

1. BREMBECK FH, ROSARIO M, BIRCHMEIER W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006; 16: 51-59. doi:10.1016/j.gde.2005.12.007
2. LEE HC, KIM M, WANDS JR. Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci 2006; 11: 1901-1915. doi:10.2741/1933
3. LEE HS, PARK MH, YANG SJ, PARK KC, KIM NS, et al. Novel candidate targets of Wnt/beta-catenin signaling in hepatoma cells. Life Sci 2007; 80: 690-698. doi:10.1016/j.lfs.2006.10.024
4. OGASAWARA N, TSUKAMOTO T, MIZOSHITA T, INADA K, CAO X, et al. Mutations and nuclear accumulation of beta-catenin correlate with intestinal phenotypic expression in human gastric cancer. Histopathology 2006; 49: 612-621. doi:10.1111/j.1365-2559.2006.02560.x
5. OZAKI S, IKEDA S, ISHIZAKI Y, KURIHARA T, TOKUMOTO N, et al. Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep 2005; 14: 1437-1443.
6. MARTENSSON A, OBERG A, JUNG A, CEDERQUIST K, STENLING R, et al. Beta-catenin expression in relation to genetic instability and prognosis in colorectal cancer. Oncol Rep 2007; 17: 447-452.
7. SETO ES, BELLEN HJ. The ins and outs of Wingless signaling. Trends Cell Biol 2004; 14: 45-53. doi:10.1016/j.tcb.2003.11.004
8. WADA T, PENNINGER JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23: 2838-2849. doi:10.1038/sj.onc.1207556
9. ATSUMI T, KATO K, UNO K, IIJIMA K, KOIKE T, et al. Pathophysiological role of the activation of p38 mitogen- activated protein kinases in poorly differentiated gastric cancer. Pathol Int 2007; 57: 635-644. doi:10.1111/j.1440-1827.2007.02152.x
10. MICHL P, DOWNWARD J. Mechanisms of disease: PI3K/ AKT signaling in gastrointestinal cancers. Z Gastroenterol 2005; 43: 1133-1139. doi:10.1055/s-2005-858638
11. BESSARD A, FREMIN C, EZAN F, FAUTREL A, GAILHOUSTE L, et al. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene 2008; 27: 5315-5325. doi:10.1038/onc.2008.163
12. NAKANISHI K, SAKAMOTO M, YAMASAKI S, TODO S, HIROHASHI S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005; 103: 307-312. doi:10.1002/cncr.20774
13. ZHU L, HU C, LI J, XUE P, HE X, et al. Real-time imaging nuclear translocation of Akt1 in HCC cells. Biochem Biophys Res Commun 2007; 356: 1038-1043. doi:10.1016/j.bbrc.2007.03.092
14. MOUNTZIOS G, PLANCHARD D, BESSE B, VALIDIRE P, GIRARD P, et al. Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers. Clin Cancer Res 2008; 14: 4096-4102. doi:10.1158/1078-0432.CCR-07-4150
15. [15] BLEEKER FE, FELICIONI L, BUTTITTA F, LAMBA S, CARDONE L, et al. AKT1(E17K) in human solid tumours. Oncogene 2008; 26: Epub ahead of print.
16. SOUNG YH, LEE JW, NAM SW, LEE JY, YOO NJ, et al. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology 2006; 70: 285-289. doi:10.1159/000096289
17. CHUNG H, SEO S, MOON M, PARK S. Phosphatidylinositol-3-kinase/Akt/ glycogen synthase kinase-3 beta and ERK1/2 pathways mediate protective effects of acylated and unacylated ghrelin against oxygen-glucose deprivation-induced apoptosis in primary rat cortical neuronal cells. J Endocrinol 2008; 198: 511-521. doi:10.1677/JOE-08-0160
18. SUMI T, TSUNEYOSHI N, NAKATSUJI N, SUEMORI H. Defining early lineage specification of human embryonic stem cells by the orchestrated balance of canonical Wnt/beta-catenin, Activin/Nodal and BMP signaling. Development 2008; 135: 2969-2979. doi:10.1242/dev.021121
19. SCHOHL A, FAGOTTO F. Beta-catenin, MAPK and Smad signaling during early Xenopus development. Development 2002; 129: 37-52.
20. THORNTON TM, Pedraza-Alva G, DENG B, WOOD CD, ARONSHTAM A, et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008; 320: 667-670. doi:10.1126/science.1156037
21. BANK U, REINHOLD D, ANSORGE S. Measurement of cellular activity with the MTT test. Optimization of the method. Allerg Immunol (Leipz) 1991; 37:119-123.
22. DUXBURY MS, WHANG EE. RNA interference: A Practical Approach. J Surg Res 2004; 117: 339-344. doi:10.1016/j.jss.2003.09.010
23. HARBORTH J, ELBASHIR SM, VANDENBURGH K, MANNINGA H, SCARINGE SA, et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 2003; 13: 83-105. doi:10.1089/108729003321629638
24. VERMA UN, SURABHI RM, SCHMALTIEG A, BECERRA C, GAYNOR RB. Small interfering RNAs directed against beta-Catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003; 9: 1291-1300.
25. EI TOUNY LH, BANERJEE PP. Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype. Carcinogenesis 2007; 28: 1710-1717. doi:10.1093/carcin/ bgm103
26. LU J, RHO O, WILKER E, BELTRAN L, DIGIOVANNI J. Activation of epidermal akt by diverse mouse skin tumor promoters. Mol Cancer Res 2007; 5: 1342-1352. doi:10.1158/ 1541-7786.MCR-07-0115
27. KATSO R, OKKENHAUG K, AHMADI K, WHITE S, TIMMS J, et al. Cellular function of phosphoinositide 3-kinases: im-plications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17: 615-675. doi:10.1146/annurev.cellbio.17.1.615
28. ASSELIN E, MILLS GB, TSANG BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatininduced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001; 61: 1862-1868.
29. PARK S, KIM D, KANEKO S, SZEWCZYK KM, NICOSIA SV, et al. Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway. J Biol Chem 2005; 280: 38932-38941. doi:10.1074/jbc.M504011200